The agency said that although the Akeega with prednisone improved outcomes in all patients with HRR mutations, the benefits were driven by those with BRCA2 mutations.

A large international analysis found no adverse effect of menopausal hormonal therapy among women with high genetic cancer risks.

NEW YORK – TransCode Therapeutics' microRNA-10b inhibitor TTX-MC138 will be included in a Phase II branch of the PRE-I-SPY trial, the company announced Thursday.

Black patients were less likely to receive PARP inhibitors, despite having BRCA1/2 testing and positivity rates comparable to White patients, and were at higher risk of death.

The financing comes as the FDA has lifted a clinical hold on the firm's MyPEAK-1 trial testing TN-201 in MYBPC3-associated hypertrophic cardiomyopathy.

The AI-driven platform identifies cell cycle deregulation and tumor immune microenvironment dynamics from biopsy images.

The SERD improved survival endpoints compared to standard adjuvant endocrine therapy in a Phase III trial that may support ...

Although the readout was only from four multiple myeloma patients, attendees at the meeting wondered at how far the CAR T-cell therapy field has come.

Once the exchange agreements close, Sarepta will have $893.4 million in debt due in 2030 following previous refinancing it announced in August.

Challenging federal funding cuts, minimal residual disease, and a busy field of CAR T-cell candidates characterized this year ...

At SABCS, Mayo Clinic researchers reported PRS data was more likely to change the risk categories of people with variants in moderate risk penetrance genes.